Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Teva Pharmaceutical Industries has acquired Cephalon, following which Cephalon became a wholly owned subsidiary of Teva.
Subscribe to our email newsletter
The combined company will have its presence established in more than 60 countries and generated nearly $20bn revenues on a pro-forma basis for the twelve months ended June 2011.
Teva president and CEO Shlomo Yanai said the deal would strengthen their specialty pharmaceuticals business through diversification and expansion of their product.
"Our newly-expanded portfolio in CNS, Oncology, Respiratory and Women’s Health along with our robust pipeline of more than 30 late-stage products truly cements our position as a leader in specialty pharma," Yanai added.